BMJ  2007;335:136 (21 July), doi:10.1136/bmj.39261.471806.55 (published 5 July 2007)

Research

Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study

¹ Tower Building, University Park, Nottingham NG2 7RD, ² Centre for Health Sciences, Queen Mary's School of Medicine and Dentistry, London, ³ Department of Social Medicine, University of Bristol, ⁴ Avon Primary Care Research Collaborative, Bristol Primary Care Trust

Objective To derive a new cardiovascular disease risk score (QRISK) for the United Kingdom and to validate its performance against the established Framingham cardiovascular disease algorithm and a newly developed Scottish score (ASSIGN).

Design Prospective open cohort study using routinely collected data from general practice.

Setting UK practices contributing to the QRESEARCH database.

Participants The derivation cohort consisted of 1.28 million patients, aged 35-74 years, registered at 318 practices between 1 January 1995 and 1 April 2007 and who were free of diabetes and existing cardiovascular disease. The validation cohort consisted of 0.61 million patients from 160 practices.

Main outcome measures First recorded diagnosis of cardiovascular disease (incident diagnosis between 1 January 1995 and 1 April 2007): myocardial infarction, coronary heart disease, stroke, and transient ischaemic attacks. Risk factors were age, sex, smoking status, systolic blood pressure, ratio of total serum cholesterol to high density lipoprotein, body mass index, family history of coronary heart disease in first degree relative aged less than 60, area measure of deprivation, and existing treatment with antihypertensive agent.

Results A cardiovascular disease risk algorithm (QRISK) was developed in the derivation cohort. In the validation cohort the observed 10 year risk of a cardiovascular event was 6.60% (95% confidence interval 6.48% to 6.72%) in women and 9.28% (9.14% to 9.43%) in men. Overall the Framingham algorithm over-predicted cardiovascular disease risk at 10 years by 35%, ASSIGN by 36%, and QRISK by 0.4%. Measures of discrimination tended to be higher for QRISK than for the Framingham algorithm and it was better calibrated to the UK population than either the Framingham or ASSIGN models. Using QRISK 8.5% of patients aged 35-74 are at high risk (20% risk or higher over 10 years) compared with 13% when using the Framingham algorithm and 14% when using ASSIGN. Using QRISK 34% of women and 73% of men aged 64-75 would be at high risk compared with 24% and 86% according to the Framingham algorithm. UK estimates for 2005 based on QRISK give 3.2 million patients aged 35-74 at high risk, with the Framingham algorithm predicting 4.7 million and ASSIGN 5.1 million. Overall, 53 668 patients in the validation dataset (9% of the total) would be reclassified from high to low risk or vice versa using QRISK compared with the Framingham algorithm.

Conclusion QRISK performed at least as well as the Framingham model for discrimination and was better calibrated to the UK population than either the Framingham model or ASSIGN. QRISK is likely to provide more appropriate risk estimates to help identify high risk patients on the basis of age, sex, and social deprivation. It is therefore likely to be a more equitable tool to inform management decisions and help ensure treatments are directed towards those most likely to benefit. It includes additional variables which improve risk estimates for patients with a positive family history or those on antihypertensive treatment. However, since the validation was performed in a similar population to the population from which the algorithm was derived, it potentially has a "home advantage." Further validation in other populations is therefore required.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores

Julia Hippisley-Cox and Carol Coupland
BMJ 2009 339: b4229. [Abstract] [Full Text] [PDF]

Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls

Jonathan A C Sterne, Ian R White, John B Carlin, Michael Spratt, Patrick Royston, Michael G Kenward, Angela M Wood, and James R Carpenter
BMJ 2009 338: b2393. [Full Text]

QRISK may be less useful

Su May Liew and Paul Glasziou
BMJ 2009 339: b3485. [Extract] [Full Text]

Bespoke cohort studies needed

Richard Morris, Irene Petersen, Louise Marston, Kate Walters, James Carpenter, and Irwin Nazareth
BMJ 2009 339: b3512. [Extract] [Full Text]

ASSIGN, QRISK, and validation

Hugh Tunstall-Pedoe, Mark Woodward, and Graham Watt
BMJ 2009 339: b3514. [Extract] [Full Text]

Authors’ reply

Gary S Collins and Douglas G Altman
BMJ 2009 339: b3516. [Extract] [Full Text]

Heart risk scoring system used by NICE may overestimate lipid disorders

Zosia Kmietowicz
BMJ 2009 339: b3273. [Extract] [Full Text]

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis

Nicholas Latimer, Joanne Lord, Robert L Grant, Rachel O’Mahony, John Dickson, Philip G Conaghan on behalf of the National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group
BMJ 2009 339: b2538. [Abstract] [Full Text] [PDF]

An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study

Gary S Collins and Douglas G Altman
BMJ 2009 339: b2584. [Abstract] [Full Text] [PDF]

QRISK or Framingham for predicting cardiovascular risk?

Rod Jackson, Roger Marshall, Andrew Kerr, Tania Riddell, and Sue Wells
BMJ 2009 339: b2673. [Extract] [Full Text]

Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore

Julia Hippisley-Cox, Carol Coupland, John Robson, Aziz Sheikh, and Peter Brindle
BMJ 2009 338: b880. [Abstract] [Full Text] [PDF]

Evaluating cardiovascular risk assessment for asymptomatic people

Ian A Scott
BMJ 2009 338: a2844. [Extract] [Full Text]

Cardiovascular risk models

Luc Bonneux
BMJ 2007 335: 107-108. [Extract] [Full Text] [PDF]

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

Julia Hippisley-Cox and Carol Coupland
BMJ 2005 330: 1366. [Abstract] [Full Text] [PDF]

Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis

Julia Hippisley-Cox and Carol Coupland
BMJ 2005 330: 1059-1063. [Abstract] [Full Text] [PDF]

Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study

Peter Brindle, Jonathan Emberson, Fiona Lampe, Mary Walker, Peter Whincup, Tom Fahey, and Shah Ebrahim
BMJ 2003 327: 1267. [Abstract] [Full Text] [PDF]

Prehospital thrombolysis

Bernard D Prendergast
BMJ 2003 327: 1-2. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Hippisley-Cox, J., Coupland, C. (2009). Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 339: b4229-b4229 [Abstract] [Full text]  
• Cooney, M. T., Dudina, A. L., Graham, I. M. (2009). Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians.. J Am Coll Cardiol 54: 1209-1227 [Abstract] [Full text]  
• Sterne, J. A C, White, I. R, Carlin, J. B, Spratt, M., Royston, P., Kenward, M. G, Wood, A. M, Carpenter, J. R (2009). Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338: b2393-b2393 [Full text]  
• Liew, S. M., Glasziou, P. (2009). QRISK may be less useful. BMJ 339: b3485-b3485 [Full text]  
• Morris, R., Petersen, I., Marston, L., Walters, K., Carpenter, J., Nazareth, I. (2009). Bespoke cohort studies needed. BMJ 339: b3512-b3512 [Full text]  
• Tunstall-Pedoe, H., Woodward, M., Watt, G. (2009). ASSIGN, QRISK, and validation. BMJ 339: b3514-b3514 [Full text]  
• Collins, G. S, Altman, D. G (2009). Authors' reply. BMJ 339: b3516-b3516 [Full text]  
• Latimer, N., Lord, J., Grant, R. L, O'Mahony, R., Dickson, J., Conaghan, P. G, on behalf of the National Institute for Health and, (2009). Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 339: b2538-b2538 [Abstract] [Full text]  
• Collins, G. S, Altman, D. G (2009). An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ 339: b2584-b2584 [Abstract] [Full text]  
• Jackson, R., Marshall, R., Kerr, A., Riddell, T., Wells, S. (2009). QRISK or Framingham for predicting cardiovascular risk?. BMJ 339: b2673-b2673 [Full text]  
• Pencina, M. J., D'Agostino, R. B. Sr, Larson, M. G., Massaro, J. M., Vasan, R. S. (2009). Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study. Circulation 119: 3078-3084 [Abstract] [Full text]  
• Banerjee, A., Silver, L. E., Heneghan, C., Welch, S. J.V., Bull, L. M., Mehta, Z., Banning, A. P., Rothwell, P. M. (2009). Sex-Specific Familial Clustering of Myocardial Infarction in Patients With Acute Coronary Syndromes. Circ Cardiovasc Genet 2: 98-105 [Abstract] [Full text]  
• Hippisley-Cox, J., Coupland, C., Robson, J., Sheikh, A., Brindle, P. (2009). Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 338: b880-b880 [Abstract] [Full text]  
• Hingorani, A. D., Shah, T., Casas, J. P., Humphries, S. E., Talmud, P. J. (2009). C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target?. Clin. Chem. 55: 239-255 [Abstract] [Full text]  
• Kerr, A J, Broad, J, Wells, S, Riddell, T, Jackson, R (2009). Should the first priority in cardiovascular risk management be those with prior cardiovascular disease?. Heart 95: 125-129 [Abstract] [Full text]  
• Scott, I. A (2009). Evaluating cardiovascular risk assessment for asymptomatic people. BMJ 338: a2844-a2844 [Full text]  
• Ridker, P. M, Paynter, N. P., Rifai, N., Gaziano, J. M., Cook, N. R. (2008). C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men. Circulation 118: 2243-2251 [Abstract] [Full text]  
• McGeechan, K., Macaskill, P., Irwig, L., Liew, G., Wong, T. Y. (2008). Assessing New Biomarkers and Predictive Models for Use in Clinical Practice: A Clinician's Guide. Arch Intern Med 168: 2304-2310 [Abstract] [Full text]  
• Bulugahapitiya, U, Siyambalapitiya, S, Sithole, J, Fernando, D J, Idris, I (2008). Age threshold for vascular prophylaxis by aspirin in patients without diabetes. Heart 94: 1429-1432 [Abstract] [Full text]  
• Robson, J (2008). Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Heart 94: 1331-1332 [Full text]  
• Mainous, A. G. III, Everett, C. J., Player, M. S., King, D. E., Diaz, V. A. (2008). Importance of a Patient's Personal Health History on Assessments of Future Risk of Coronary Heart Disease. J Am Board Fam Med 21: 408-413 [Abstract] [Full text]  
• Young, L. E (2008). QRISK underestimated risk of cardiovascular disease in general practice patients; Framingham score overestimated risk. Evid. Based Nurs. 11: 91-91 [Full text]  
• Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., Minhas, R., Sheikh, A., Brindle, P. (2008). Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336: 1475-1482 [Abstract] [Full text]  
• Ix, J. H., Allison, M. A., Denenberg, J. O., Cushman, M., Criqui, M. H. (2008). Novel cardiovascular risk factors do not completely explain the higher prevalence of peripheral arterial disease among African Americans. The San Diego Population Study.. J Am Coll Cardiol 51: 2347-2354 [Abstract] [Full text]  
• Wierzbicki, A. S, Purdon, S. D, Hardman, T. C, Kulasegaram, R., Peters, B. S (2008). Review: Clinical aspects of the management of HIV lipodystrophy. British Journal of Diabetes & Vascular Disease 8: 113-119 [Abstract]  
• Graffy, J. (2008). Engaging family practitioners in research: are we getting it right?. Fam Pract 25: 69-70 [Full text]  
• D'Agostino, R. B. Sr, Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., Kannel, W. B. (2008). General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study. Circulation 117: 743-753 [Abstract] [Full text]  
• Ingelsson, E., Pencina, M. J., D'Agostino, R. B., Vasan, R. S. (2008). Utility of Different Lipid Measures to Predict Coronary Heart Disease Reply. JAMA 299: 36-36 [Full text]  
• Hippisley-Cox, J, Coupland, C, Vinogradova, Y, Robson, J, Brindle, P (2008). Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 94: 34-39 [Abstract] [Full text]  
• Preiss, D., Sattar, N. (2007). Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence. Heart 93: 1493-1496 [Abstract] [Full text]  
• (2007). Comparison of Cardiovascular Risk Models. Journal Watch Cardiology 2007: 5-5 [Full text]  
• Bonneux, L. (2007). Cardiovascular risk models. BMJ 335: 107-108 [Full text]  

Rapid Responses:

Read all Rapid Responses

Does QRISK describe a partially treated population?

Eugene M.G. Milne
bmj.com, 6 Jul 2007 [Full text]

QRISK can NOT be used for treatment decisions

L S Lewis
bmj.com, 8 Jul 2007 [Full text]

QRisk better than Framingham ?

Michel J. Romanens
bmj.com, 9 Jul 2007 [Full text]

Doubts about QRISK score: total / HDL cholesterol should be important.

Richard Peto
bmj.com, 13 Jul 2007 [Full text]

QRISK and health inequalities

John Macleod, et al.
bmj.com, 13 Jul 2007 [Full text]

FRAMINGHAM, ASSIGN and QRISK Cardiovascular Risk Scores

Hugh Tunstall-Pedoe, et al.
bmj.com, 14 Jul 2007 [Full text]

QRISK has great potential, but don't underestimate Framingham

William G Simpson, et al.
bmj.com, 15 Jul 2007 [Full text]

QRISK - Methodological limitations?

Marie Therese Cooney, et al.
bmj.com, 18 Jul 2007 [Full text]

Measures of smoking, deprivation and cardiovascular risk

Sarah H Wild, et al.
bmj.com, 20 Jul 2007 [Full text]

QRISK still leaves patients at risk or unnecessarily treated

Gordon A A Ferns
bmj.com, 21 Jul 2007 [Full text]

Waist to Hip ratio should be included

Ben D Ewald
bmj.com, 23 Jul 2007 [Full text]

QRISK - authors response

Julia Hippisley-Cox, et al.
bmj.com, 7 Aug 2007 [Full text]

Multiple imputation needs to be used with care and reported in detail

John B Carlin, et al.
bmj.com, 21 Aug 2007 [Full text]

Setting for risk calculation will affect performance of QRISK

Richard J McManus, et al.
bmj.com, 21 Aug 2007 [Full text]

Powerful stratification tool

Guy Wilkinson
bmj.com, 24 Aug 2007 [Full text]

QRISK validation study published

Peter M Brindle
bmj.com, 18 Oct 2007 [Full text]

Are risk calculators answering the wrong question?

G Alastair Cooke
bmj.com, 31 Oct 2007 [Full text]

Online poll

Find out more on doc2doc >>